An international team of scientists is actively developing a vaccine against the deadly hantavirus, a critical effort spurred by a recent outbreak on a luxury cruise ship, the MV Hondius, which tragically resulted in three deaths. This initiative addresses an urgent global health concern given the virus's severity and lack of approved treatments.

Hantavirus, a rat-borne pathogen, currently lacks a specific approved cure or vaccine. If it progresses to the more severe Hantavirus Pulmonary Syndrome (HPS), it can be fatal in approximately 40% of infected patients. The disease often presents with early symptoms similar to the flu or Covid-19, including fever, fatigue, and muscle aches, which can lead to delayed diagnosis and medical intervention. Depending on the strain, hantavirus can lead to either HPS, primarily affecting the lungs, or Hemorrhagic Fever with Renal Syndrome (HFRS), impacting the kidneys. Both severe forms can result in organ failure and death. Importantly, the Andes strain, identified in the recent cruise ship outbreak, is transmissible between people, raising concerns about wider global spread.

The recent mid-Atlantic outbreak on the MV Hondius brought hantavirus into international focus. While experts are investigating whether the outbreak originated from rodent contamination on the vessel or if passengers were exposed prior to boarding, new reports suggest a possible link to a birdwatching trip where some passengers visited a rubbish tip before departure. Given the incubation period of up to eight weeks, passengers might not have felt unwell until after the ship had sailed, complicating containment efforts. Officials are now scrambling to contact and test dozens of passengers who have already disembarked, encouraging them to isolate if necessary. Currently, two British individuals are self-isolating, with 20 more awaiting repatriation.

In response to this urgent global health threat, an international team of scientists, including researchers from the University of Bath, is making significant strides in vaccine development. They have successfully developed a new antigen specifically targeting Hantaan disease, which belongs to the hantavirus group. Laboratory and animal testing of this vaccine candidate have shown 'excellent' immune responses, indicating promising potential. Professor Asel Sartbaeva, a key figure in the project, emphasized the transformative impact a vaccine would have in preventing disease instances or at least mitigating the severe consequences of infection.

Beyond efficacy, the researchers are also innovating in vaccine storage and delivery. A crucial aspect of their work is developing a vaccine that does not require freezing temperatures, which traditionally complicates transportation, particularly to remote or underserved regions. This is achieved through a process called ensilication, where vaccines are encased in tiny layers of material to enhance their resistance to temperature fluctuations. The long-term vision is to enable delivery of these thermally stable vaccines by drones, ensuring rapid deployment to populations most in need during outbreaks.

While vaccine development progresses, early medical intervention remains the primary method to combat the virus. However, the initial flu-like symptoms often lead to delays in seeking medical support until the infection is advanced. At later stages, patient care typically involves oxygen therapy, mechanical ventilation, and even dialysis to address severe complications like lung damage and kidney failure. The extended incubation period of up to eight weeks further complicates detection and creates opportunities for undetected spread, underscoring the critical need for a readily available and effective preventative vaccine.